Gold-Mediated Modification of Apoferritin Surface with Targeting Antibodies

To ensure targeting of apoferritin nanocarrier with encapsulated doxorubicin drug, we used a peptide linker based on a protein G with N-terminus affinity towards Fc region of antibodies. To connect the peptide to the surface of apoferritin, the C-terminus of peptide was made of cysteine with affinity to gold. The surface of apoferritin with encapsulated doxorubicin (APODOX) was coated either with gold nanoparticles (APODOX-Nano) or gold(III) chloride hydrate reduced with sodium borohydride (APODOX-HAu). The reduction with sodium borohydride caused a loss of doxorubicin fluorescent properties and probably accompanied with the loss of its biological activity. Fluorescent properties of APODOX-Nano were similar to the unmodified APODOX; therefore it was more suited for the intended use. To evaluate the specificity of apoferritin modified with antibodies, ELISA-like method was used with the surface of microtitration plate wells coated by the antigen (goat anti-human IgG antibodies). To these wells, the nanocarrier was applied. APODOX without the modification showed 5× lower affinity to the antigen than APODOX-Nano modified gold and targeting antibodies (human IgG antibodies).




References:
[1] Drbohlavova, J. et al. Nanocarriers for Anticancer Drugs - New Trends
in Nanomedicine. Current Drug Metabolism, 2013, vol. 14, no. 5, pp.
547-564. ISSN 1389-2002.
[2] Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy.
Nature Nanotechnology, 2007, vol. 2, no. 12, pp. 751-760. ISSN 1748-
3387.
[3] Allen, T. M. a Cullis, P. R. Drug delivery systems: Entering the
mainstream. Science, 2004, vol. 303, no. 5665, pp. 1818-1822. ISSN
0036-8075.
[4] Sumer, B. a Gao, J. M. Theranostic nanomedicine for cancer.
Nanomedicine, 2008, vol. 3, no. 2, pp. 137-140. ISSN 1743-5889.
[5] Svenson, S. Theranostics: Are we there yet? Molecular Pharmaceutics,
2013, vol. 10, no. 3, pp. 848-856. ISSN 1543-8384.
[6] Panyam, J. a Labhasetwar, V. Biodegradable nanoparticles for drug and
gene delivery to cells and tissue. Advanced Drug Delivery Reviews,
2003, vol. 55, no. 3, pp. 329-347. ISSN 0169-409X.
[7] Kopp, R. et al. Free apoferritin + apoferritin obtained by reduction of
iron-containing ferritin. Nature, 1964, vol. 202, no. 493, pp. 1211-1212.
ISSN 0028-0836.
[8] Asano, T. et al. Distinct mechanisms of ferritin delivery to lysosomes in
iron-depleted and iron-replete cells. Molecular and Cellular Biology,
2011, vol. 31, no. 10, pp. 2040-2052. ISSN 0270-7306.
[9] Crichton, R. R. a Declercq, J. P. X-ray structures of ferritins and related
proteins. Biochimica Et Biophysica Acta-General Subjects, 2010, vol.
1800, no. 8, pp. 706-718. ISSN 0304-4165.
[10] Haussler, W. Structure and dynamics in apoferritin solutions with
paracrystalline order. Chemical Physics, 2003, vol. 292, no. 2-3, pp.
425-434. ISSN 0301-0104.
[11] Kim, M. et al. pH-Dependent Structures of Ferritin and Apoferritin in
Solution: Disassembly and Reassembly. Biomacromolecules, 2011, vol.
12, no. 5, pp. 1629-1640. ISSN 1525-7797.
[12] Wong, P. et al. A method to quantitative coomassie blue-stained proteins
in cylindrical polyacrylamide gels. Analytical Biochemistry, 1985, vol.
150, no. 2, pp. 288-293. ISSN 0003-2697.
[13] Kilic, M. A. et al. A novel protein-based anticancer drug encapsulating
nanosphere: apoferritin-doxorubicin complex. Journal of Biomedical
Nanotechnology, 2012, vol. 8, no. 3, pp. 508-514. ISSN 1550-7033.
[14] Fan, K. L. et al. Human ferritin for tumor detection and therapy. Wiley
Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology, 2013,
vol. 5, no. 4, pp. 287-298. ISSN 1939-5116.
[15] Yang, H. et al. Hexamer peptide affinity resins that bind the Fc region of
human immunoglobulin G. Journal of Peptide Research, 2005, vol. 66,
pp. 120-137. ISSN 1397-002X.
[16] Hakkinen, H. The gold-sulfur interface at the nanoscale. Nature
Chemistry, 2012, vol. 4, no. 6, pp. 443-455. ISSN 1755-4330.